Organon & Co.

NYSE:OGN

Drug Manufacturers - General

Healthcare
$13.92 +0.04%

+$0.01 today

Market cap
$3.66B
Beta
1.54
P/E (TTM)
14.2
EPS (TTM)
$0.94
Dividend yield
0.60%
52W Low $5.69High $13.49

Volume 3.90M

Average 8.57M

OGN Long-term Debt

Borrowings due after more than one year.

Organon & Co.NYSE: OGN

Long-term Debt · Q3 FY2026 · quarter ended Sep 2026

Long-term debt falls 3.4% from a year ago

Long-term debt stood at $8.49B at the end of Q3 FY2026, down 3.4% from a year earlier and up 0.1% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.

Context

  • Long-term debt amounted to 63.3% of total assets at the end of Q3 FY2026, down 1.5 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -3.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$8.49B+0.1% QoQ
Last fiscal yearDec 2025
$8.64B-2.5% YoY
Year agoSep 2025
$8.78B-3.4% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year-2.5%——
3-year CAGR-1.0%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
8.64B USD
Year-over-year change
-2.5%
4-year CAGR
-1.4%

Long-term Debt vs competitors

How OGN compares with its peers on the latest reported figures

  • OGN's Sep 2026 long-term debt of $8.49B is the highest of the 10 companies compared; the peer median is $244.53M.
  • Its year-over-year change of -3.4% is the 5th highest of 8, against a peer median of +0.2%.
  • Long-term debt amounts to 63.3% of total assets for OGN, versus a peer median of 18.6%.
OGN Competitors Peer median
Long-term Debt for OGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OGNOrganon & Co.Sep 2026$8.49B -3.4%-1.0%63.3%
SEMSelect Medical Holdings CorporationMar 2026$1.84B +3.9%-12.4%30.4%
ALVOAlvotechMar 2026$1.27B +19.1%+19.2%89.2%
PAHCPhibro Animal Health CorporationMar 2026$712.69M +0.2%+18.9%49.3%
MDPediatrix Medical Group, Inc.Sep 2026$397.77M -31.1%-1.8%18.6%
NUVBNuvation Bio Inc.Jun 2026$244.53M +420.6%—32.8%
TLRYTilray Brands, Inc.Feb 2026$223.25M -39.0%-21.1%10.8%
HRMYHarmony Biosciences Holdings, Inc.Jun 2026$133.96M -12.6%-7.9%9.8%
GRDNGuardian Pharmacy Services, Inc.Jun 2026$0 ——0.0%
AUPHAurinia Pharmaceuticals Inc.Jun 2026$0 ——0.0%
Peer median (excluding OGN) $244.53M+0.2%-4.8%18.6%

Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents737M706M693M675M574M
Short-term Investments00000
Net Receivables1.51B1.61B1.86B1.49B1.43B
Inventory915M1B1.32B1.32B1.41B
Other Current Assets596M616M643M861M939M
Total Current Assets3.76B3.93B4.51B4.35B4.35B
Property, Plant & Equipment (Net)1.2B1.23B1.36B1.33B1.3B
Goodwill4.6B4.6B4.6B4.68B4.15B
Intangible Assets651M649M533M1.41B1.13B
Long-term Investments00027M0
Tax Assets0267M808M946M0
Other Non-current Assets464M272M250M361M1.93B
Total Non-current Assets6.92B7.02B7.55B8.75B8.52B
Total Assets10.68B10.96B12.06B13.1B12.87B
Account Payables1.38B1.13B1.31B1.15B952M
Short-term Debt55M57M55M64M56M
Tax Payables185M184M206M134M0
Deferred Revenue00000
Other Current Liabilities975M1.14B1.34B1.37B1.3B
Total Current Liabilities2.6B2.51B2.92B2.72B2.39B
Long-term Debt9.13B8.91B8.75B8.86B8.64B
Deferred Tax Liabilities4M19M47M74M57M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities279M261M287M865M924M
Total Non-current Liabilities9.59B9.34B9.21B9.91B9.73B
Total Liabilities12.19B11.85B12.13B12.63B12.12B
Common Stock3M3M3M3M3M
Retained Earnings(998M)(331M)443M1.01B1.11B
Accumulated OCI(513M)(564M)(541M)(649M)(527M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity(1.51B)(892M)(70M)472M752M
Total Debt9.36B9.11B8.93B9.04B8.8B
Net Debt8.63B8.41B8.24B8.36B8.23B

Organon & Co.

NYSE:OGN

Intrinsic Alpha fair value

Locked

Current Price

$13.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.